+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators



Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators



Clinical Cancer Research 6(2): 578-584



New prognosticators are needed for breast cancer patients after the initial surgical treatment to make therapeutic decisions that ultimately will affect their DFS. These consist of specific proteolytic enzymes including lysosomal endopeptidases. In this study, the activity and protein concentrations of cathepsins (Cats) D, B, and L were measured in 282 invasive breast tumor cytosols. These potential biological prognostic indicators were compared with other histopathological parameters, such as tumor size, lymph node involvement, tumor-node-metastasis stage, histological grade, DNA analysis, and steroid receptors. CatD protein concentration correlated with lymph node involvement. CatB and CatL levels correlated significantly with Scarf-Bloom-Richardson histological grade and were also higher in estrogen-negative tumors, and CatB was higher in larger tumors. As prognostic markers, CatB concentration was significant for increased risk for recurrence in the entire patient population and specifically also in lymph node-negative patients as follows: high CatB concentration (above 371 micrograms/g) in tumor cytosols was significant (P < 0.00) for high risk of recurrence but was of only borderline prognostic significance (P < 0.06) for overall survival of all patients. In lymph node-negative patients, CatB (above 240 micrograms/g, P < 0.003) was highly significant for recurrence-free survival, followed by CatL (above 20 micrograms/g, P < 0.049) and CatD (above 45 nmol/g, P < 0.044) concentrations. For overall survival of node-negative patients, only CatB was a significant (P < 0.014) prognosticator. We conclude that CatB is useful as a prognostic indicator in lymph node-negative patients. This suggests that selective adjuvant therapy should be applied in this lower risk group of patients when high levels of CatB are determined.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045457107

Download citation: RISBibTeXText

PMID: 10690542


Related references

Cathepsin d and other markers as prognostic indicators for node negative breast cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 32: 164, 1991

Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Research 52(19): 5198-5203, 1992

Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients. Breast Cancer Research and Treatment 60(2): 173-179, 2000

Is cathepsin D A useful prognostic factor in localized, lymph node-negative breast cancer?. International Journal of Oncology 5(Suppl. ): 369, 1994

Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. International Journal of Biological Markers 23(3): 161-168, 2008

Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Cancer Detection and Prevention 26(1): 42-49, 2002

Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue. Biological Chemistry 382(5): 799-804, 2001

Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay. Cancer. 79(11): 2132-2136, 1997

Serum cathepsin B levels, urinary excretion of cathepsin B and cancer tissue content of cathepsin B in patients with breast cancer. Medical Science Research 22(1): 31-32, 1994

A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index. Plos one 8(12): E83081, 2013

Cathepsin-d activity levels in colorectal-cancer - correlation with cathepsin-B and cathepsin-L and other biological and clinical-parameters. International Journal of Oncology 5(3): 509-515, 1994

Serum cathepsin B levels, urinary excretion of cathepsin B and tissue cathepsin B content in the patients with gastric cancer. Nihon Geka Hokan. Archiv für Japanische Chirurgie 62(5): 217-221, 1993

Cathepsin b in human breast tumors correlation with cathepsin d and other prognostic factors. Breast Cancer Research & Treatment 16(2): 181, 1990

Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D. European Journal of Cancer 29A(9): 1248-1251, 1993

Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors. International Journal of Oncology 18(4): 793-800, 2001